3,4-Methylenedioxymethamphetamine (MDMA)
2025P012039
Phase 2 small_molecule active
Quick answer
3,4-Methylenedioxymethamphetamine (MDMA) for Post Traumatic Stress Disorder is a Phase 2 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Post Traumatic Stress Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active